Last $0.92 USD
Change Today +0.001 / 0.11%
Volume 51.2K
CDXC On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

chromadex corp (CDXC) Snapshot

Open
$0.93
Previous Close
$0.92
Day High
$0.94
Day Low
$0.91
52 Week High
03/21/14 - $2.15
52 Week Low
12/16/14 - $0.80
Market Cap
97.9M
Average Volume 10 Days
117.8K
EPS TTM
$-0.09
Shares Outstanding
106.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHROMADEX CORP (CDXC)

Related News

No related news articles were found.

chromadex corp (CDXC) Related Businessweek News

No Related Businessweek News Found

chromadex corp (CDXC) Details

ChromaDex Corporation, a natural products company, through its subsidiaries, discovers, acquires, develops, and commercializes proprietary-based ingredient technologies. The company utilizes its wholly owned business units, including ingredient technologies, catalog of natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting services. It provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic, and pharmaceutical industries. The company’s products and services in development include Nicotinamide riboside, a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, and cognitive function, as well as anti-aging effects; Pterostilbene and caffeine co-crystal that are ingredients for the formulation of energy products; and Anthocyanins, which are secondary plant metabolites for use as candidates in the pharmaceutical, dietary supplement, and food colorants industries. It also provides a range of contract services ranging from routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products to elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is headquartered in Irvine, California.

63 Employees
Last Reported Date: 03/27/14

chromadex corp (CDXC) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $276.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $204.9K
Compensation as of Fiscal Year 2013.

chromadex corp (CDXC) Key Developments

ChromaDex Corporation Presents at Benchmark's Micro Cap Discovery One-on-One Conference, Dec-11-2014

ChromaDex Corporation Presents at Benchmark's Micro Cap Discovery One-on-One Conference, Dec-11-2014 . Venue: The Palmer House Hilton, 17 E. Monroe, Chicago, IL 60603, United States.

ChromaDex Corporation Announces Earnings Results for the Third Quarter Ended September 27, 2014; Provides Sales Guidance for the Year 2014

ChromaDex Corporation announced earnings results for the third quarter ended September 27, 2014. For the quarter, the company reported net sales of $4,139,710, an increase of approximately 52% as compared to $2,718,207 for the three months ended September 28, 2013. This increase was largely due to increased sales in the proprietary ingredient segment, which grew to $2,031,250, an increase of 160% as compared to the sales of $780,489 in the third quarter of 2013. The net loss attributable to common stock holders for the third quarter of 2014 was $659,653 or $0.01 loss per share as compared to a net loss of $1,250,263 or $0.01 loss per share for the third quarter of 2013. Excluding non-cash, share-based compensation expense, which is a "non-GAAP measure," would have the effect of decreasing the company's net loss for the three months ended September 27, 2014 to $228,202. The company expects sales momentum to continue through the end of the year 2014.

ChromaDex Corporation and Life Extension Announces Launch of NAD+ Cell Regenerator

ChromaDex Corporation, Life Extension announced the launch of NAD+ Cell Regenerator(TM), an innovative nutritional supplement that boosts vitality and supports healthy aging. NAD+ Cell Regenerator(TM) features the ingredient NIAGEN(TM) from ChromaDex Corp. ChromaDex developed its breakthrough patent-protected ingredient NIAGEN(TM) as the first and only commercially available brand of nicotinamide riboside (NR). NR, the active ingredient in NAD+ Cell Regenerator(TM), boosts levels of NAD+ in cells and tissue. Studies have demonstrated that increasing the levels of NAD+ can support healthy aging by stimulating mitochondrial energy production and activating sirtuin function.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CDXC:US $0.92 USD +0.001

CDXC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $103.88 USD +0.15
Eurofins Scientific SE €213.10 EUR +0.50
Sigma-Aldrich Corp $137.21 USD +0.05
View Industry Companies
 

Industry Analysis

CDXC

Industry Average

Valuation CDXC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.2x
Price/Book 21.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHROMADEX CORP, please visit www.chromadex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.